DE60040616D1 - Verfahren zur behandlung maligner zellen eines patienten und pharmazeutische zusammensetzung zu dessen anwendung - Google Patents

Verfahren zur behandlung maligner zellen eines patienten und pharmazeutische zusammensetzung zu dessen anwendung

Info

Publication number
DE60040616D1
DE60040616D1 DE60040616T DE60040616T DE60040616D1 DE 60040616 D1 DE60040616 D1 DE 60040616D1 DE 60040616 T DE60040616 T DE 60040616T DE 60040616 T DE60040616 T DE 60040616T DE 60040616 D1 DE60040616 D1 DE 60040616D1
Authority
DE
Germany
Prior art keywords
malignant cells
patient
pharmaceutical composition
treating malignant
virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60040616T
Other languages
English (en)
Inventor
Darren R Shafren
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Viralytics Ltd
Original Assignee
Viralytics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viralytics Ltd filed Critical Viralytics Ltd
Application granted granted Critical
Publication of DE60040616D1 publication Critical patent/DE60040616D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/025—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32311—Enterovirus
    • C12N2770/32332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32311—Enterovirus
    • C12N2770/32333—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32311—Enterovirus
    • C12N2770/32371—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
DE60040616T 1999-11-25 2000-11-27 Verfahren zur behandlung maligner zellen eines patienten und pharmazeutische zusammensetzung zu dessen anwendung Expired - Lifetime DE60040616D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPQ4256A AUPQ425699A0 (en) 1999-11-25 1999-11-25 A method of treating a malignancy in a subject and a pharmaceutical composition for use in same
PCT/AU2000/001461 WO2001037866A1 (en) 1999-11-25 2000-11-27 A method of treating a malignancy in a subject and a pharmaceutical composition for use in same

Publications (1)

Publication Number Publication Date
DE60040616D1 true DE60040616D1 (de) 2008-12-04

Family

ID=3818400

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60040616T Expired - Lifetime DE60040616D1 (de) 1999-11-25 2000-11-27 Verfahren zur behandlung maligner zellen eines patienten und pharmazeutische zusammensetzung zu dessen anwendung

Country Status (12)

Country Link
US (5) US7361354B1 (de)
EP (2) EP2016952B1 (de)
JP (2) JP5085825B2 (de)
AT (1) ATE411814T1 (de)
AU (1) AUPQ425699A0 (de)
CA (1) CA2422429C (de)
CY (1) CY1108692T1 (de)
DE (1) DE60040616D1 (de)
DK (1) DK1235590T3 (de)
ES (2) ES2316394T3 (de)
PT (1) PT1235590E (de)
WO (1) WO2001037866A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030035798A1 (en) * 2000-08-16 2003-02-20 Fang Fang Humanized antibodies
US7306902B2 (en) 2002-06-28 2007-12-11 Oncolyties Biotech Inc. Oncolytic viruses as phenotyping agents for neoplasms
US8491884B2 (en) 2000-05-03 2013-07-23 Oncolytics Biotech Inc. Virus clearance of neoplastic cells from mixed cellular compositions
LV12861B (lv) * 2002-06-14 2002-10-20 Aina Muceniece Imūnstimulators ar pretaudzēja aktivitāti un tā iegūšanas paņēmiens
AU2002953436A0 (en) 2002-12-18 2003-01-09 The University Of Newcastle Research Associates Limited A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis
JP2007527719A (ja) * 2004-03-11 2007-10-04 ヴィロターグ ピーティワイ リミテッド 改変された腫瘍崩壊性ウイルス
WO2006017914A1 (en) 2004-08-20 2006-02-23 Viralytics Limited Methods and compositions for treatment of hematologic cancers
ZA200702269B (en) * 2004-08-20 2008-09-25 Viralytics Ltd Methods and compositions for treatment of hematologic cancers
US20080160031A1 (en) * 2005-01-17 2008-07-03 Viralytics Limited Method and Composition for Treatment of Neoplasms
PL2826856T3 (pl) 2013-07-16 2016-06-30 Sia Latima Genetycznie stabilny onkolityczny wirus RNA, sposób jego wytwarzania i zastosowanie
SG10201801562PA (en) * 2014-02-27 2018-04-27 Viralytics Ltd Combination method for treatment of cancer
US10639337B2 (en) * 2017-09-29 2020-05-05 Technische Universität Berlin Method for treating cancer with a Coxsackievirus B3 (CVB3) variant
CN112641811A (zh) * 2020-01-20 2021-04-13 山西高等创新研究院 一种抗肿瘤病毒
EP4288140A1 (de) 2021-02-05 2023-12-13 Iovance Biotherapeutics, Inc. Adjuvante therapie für krebs
CN118086228A (zh) * 2022-11-28 2024-05-28 厦门大学 用于治疗肿瘤的柯萨奇b组1型病毒

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5585254A (en) 1987-08-21 1996-12-17 University Of Colorado Foundation, Inc. Autonomous parvovirus gene delivery vehicles and expression vectors
EP0466815A4 (en) 1989-04-05 1992-09-02 Novacell Corpporation Infectious targetted replication-defective virion
US5714374A (en) * 1990-09-12 1998-02-03 Rutgers University Chimeric rhinoviruses
CA2051289C (en) 1990-09-14 2002-11-26 Robert L. Martuza Viral mediated destruction of neoplastic cells
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
EP0591382A4 (de) 1991-06-24 1995-01-18 Univ New York De novo zellfreie synthese des picornavirus.
JPH06509578A (ja) 1991-07-26 1994-10-27 ユニバーシティ・オブ・ロチェスター 悪性細胞利用による癌治療法
US5529774A (en) 1991-08-13 1996-06-25 The Regents Of The University Of California In vivo transfer of the HSV-TK gene implanted retroviral producer cells
SE503225C2 (sv) 1991-10-30 1996-04-22 Leif Lindholm Konsult Ab Virus-antikroppskomplex för införing av virus i mammalieceller
DK0931830T3 (da) 1993-02-16 2001-06-11 Onyx Pharma Inc Cytopatiske vira til terapi og profylakse af neoplasi
US5801029A (en) 1993-02-16 1998-09-01 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and prophylaxis of neoplasia
DE69432409T2 (de) 1993-04-30 2003-12-24 Wellstat Biologics Corp Verwendung der NDV zur Herstellung eines Medikaments zur Krebsbehandlung
US5585096A (en) 1994-06-23 1996-12-17 Georgetown University Replication-competent herpes simplex virus mediates destruction of neoplastic cells
US5728379A (en) 1994-06-23 1998-03-17 Georgetown University Tumor- or cell-specific herpes simplex virus replication
US5688773A (en) 1994-08-17 1997-11-18 The General Hospital Corporation Method of selectively destroying neoplastic cells
EP0868498B1 (de) * 1995-12-22 2003-01-22 Minnesota Mining And Manufacturing Company Gemischtes druckempfindliches klebemittel
US6071742A (en) 1997-03-05 2000-06-06 Board Of Regents Of The University Of Nebraska Coxsackie virus as a vector for delivery of anti-inflammatory cytokines
US6110461A (en) 1997-08-13 2000-08-29 Oncolytics Biotech Inc. Reovirus for the treatment of neoplasia
US6136307A (en) 1997-08-13 2000-10-24 Oncolytics Biotech Inc. Reovirus for the treatment of cellular proliferative disorders
ES2292207T3 (es) 1997-10-09 2008-03-01 Wellstat Biologics Corporation Tratamiento de neoplasmas con virus clonales, sensibles al interferon.
FR2769505B1 (fr) 1997-10-10 2000-06-30 Michael Gerard Tovey Compositions de cytokines a administrer a la muqueuse buccale, et leurs utilisations
WO1999028750A1 (en) * 1997-12-03 1999-06-10 The University Of North Carolina At Chapel Hill Frnk proteins in the treatment of tumor cells
EP1061806A4 (de) 1998-03-12 2001-09-12 Univ Pennsylvania Produktive zellen für replikationsselektive viren zur behandlung bösartiger erkrankungen
US6060316A (en) 1998-06-09 2000-05-09 President And Fellows Of Harvard College Methods of targeting of viral entry
US6264940B1 (en) 1998-08-05 2001-07-24 The Research Foundation Of State University Of New York Recombinant poliovirus for the treatment of cancer
DE60039730D1 (de) 1999-02-05 2008-09-11 Arch Dev Corp Genetisch manipulierte Herpesviren zur Behandlung von Tumoren
JP2000279178A (ja) * 1999-02-24 2000-10-10 Japan Found Cancer Res ウイルスベクター
JP2003530301A (ja) 1999-04-15 2003-10-14 ウェルスタット バイオロジクス コーポレイション ウイルスを用いた新生物の処置
AU2005201079C1 (en) 1999-04-15 2008-11-06 Wellstat Biologics Corporation Treatment of neoplasms with viruses
EP1067188A1 (de) 1999-07-08 2001-01-10 Introgene B.V. Infektion mit chimärischen Adenoviren der Zellen die für den Adenoviren Serotyp 5 Coxsacki Adenoviren Rezeptor (CAR) negativ sind
DE19939095A1 (de) 1999-08-18 2001-02-22 Univ Eberhard Karls Von Coxsackieviren abgeleitetes Vektorsystem für Gentransfer
WO2001019380A2 (en) 1999-09-17 2001-03-22 Pro-Virus, Inc. Oncolytic virus
EP1227828A1 (de) 1999-11-12 2002-08-07 Oncolytics Biotech, Inc. Viren zur behandlung der zellulären proliferativen erkrankungen
EP1230378B1 (de) 1999-11-15 2007-06-06 Onyx Pharmaceuticals, Inc. Ein oncolytisches adenovirus
AU770517B2 (en) 1999-11-25 2004-02-26 Viralytics Limited A method of treating a malignancy in a subject and a pharmaceutical composition for use in same
AU2004202292B2 (en) 1999-11-25 2007-06-14 Viralytics Limited Method of Treating a Malignancy in a Subject
GB2375113B (en) 2000-01-21 2004-10-20 Biovex Ltd A modified, oncolytic, non-laboratory HSV strain and its use in treating cancer
CA2341356C (en) 2000-04-14 2011-10-11 Transgene S.A. Poxvirus with targeted infection specificity
US7306902B2 (en) 2002-06-28 2007-12-11 Oncolyties Biotech Inc. Oncolytic viruses as phenotyping agents for neoplasms
WO2002043647A2 (en) 2000-12-01 2002-06-06 University Of Ottawa Oncolytic virus
WO2002087625A1 (en) 2001-05-02 2002-11-07 Ramot At Tel-Aviv University Ltd. Composite oncolytic herpes virus vectors
EP1387694A2 (de) 2001-05-09 2004-02-11 M'S Science Corporation Zusammensetzung und verfahren zur behandlung von krebs mittels herpesviren
ATE500808T1 (de) 2001-05-11 2011-03-15 Wellstat Biologics Corp Onkolytische virustherapie
CA2352439A1 (en) 2001-07-17 2003-01-17 Patrick W. K. Lee Engineering oncolytic viruses
CA2449013C (en) 2001-07-23 2012-05-22 Onyx Pharmaceuticals, Inc. Viral mutants that selectively replicate in targeted human cancer cells
AU2003216502B2 (en) 2002-03-01 2008-04-10 Sloan-Kettering Institute For Cancer Research Prevention of recurrence and metastasis of cancer
JP2005521398A (ja) 2002-03-27 2005-07-21 ベイラー　カレッジ　オブ　メディスン 癌治療用の強力な腫瘍溶解性単純ヘルペスウイルス
WO2003092579A2 (en) 2002-04-29 2003-11-13 Hadasit Medical Research Services And Development Company Ltd. Compositions and methods for treating cancer with an oncolytic viral agent
DE03722131T1 (de) 2002-05-09 2005-09-15 Oncolytics Biotech, Inc., Calgary Methode zur schmerzbekämpfung mit onkolytischen viren
AU2002953436A0 (en) 2002-12-18 2003-01-09 The University Of Newcastle Research Associates Limited A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis
WO2005002607A2 (en) 2003-07-07 2005-01-13 Oncolytics Biotech Inc. Oncolytic reoviruses for the treatment of neoplasms having activated pp2a or rac
EP1648233A4 (de) 2003-07-08 2006-08-23 Univ Arizona Mutanten des vaccinia-virus als onkolytika
CA2540177A1 (en) 2003-09-26 2005-04-07 Novartis Ag Seneca valley virus based compositions and methods for treating disease
JP2007527719A (ja) 2004-03-11 2007-10-04 ヴィロターグ ピーティワイ リミテッド 改変された腫瘍崩壊性ウイルス
US20080292592A1 (en) 2004-04-30 2008-11-27 Sunil Chada Oncolytic Adenovirus Armed with Therapeutic Genes
WO2006002394A2 (en) 2004-06-24 2006-01-05 New York University Avirulent oncolytic herpes simplex virus strains engineered to counter the innate host response
WO2006047301A2 (en) 2004-10-21 2006-05-04 The Penn State Research Foundation Parvovirus methods and compositions for killing neoplastic cells

Also Published As

Publication number Publication date
AUPQ425699A0 (en) 1999-12-23
CA2422429A1 (en) 2001-05-31
US7361354B1 (en) 2008-04-22
EP1235590A1 (de) 2002-09-04
PT1235590E (pt) 2009-02-02
EP2016952A2 (de) 2009-01-21
CA2422429C (en) 2014-03-11
EP2016952B1 (de) 2013-12-25
US20150037287A1 (en) 2015-02-05
US20160250268A1 (en) 2016-09-01
EP1235590A4 (de) 2004-12-29
DK1235590T3 (da) 2009-02-23
JP5085825B2 (ja) 2012-11-28
ES2442000T3 (es) 2014-02-07
US20090123427A1 (en) 2009-05-14
JP2011190266A (ja) 2011-09-29
ATE411814T1 (de) 2008-11-15
EP2016952A3 (de) 2010-05-19
JP2003514870A (ja) 2003-04-22
ES2316394T3 (es) 2009-04-16
EP1235590B1 (de) 2008-10-22
US20170348366A1 (en) 2017-12-07
WO2001037866A1 (en) 2001-05-31
CY1108692T1 (el) 2014-04-09
US8722036B2 (en) 2014-05-13

Similar Documents

Publication Publication Date Title
CY1108692T1 (el) Μεθοδος θεραπειας μιας κακοηθειας σε ενα υποκειμενο και φαρμακευτικη συνθεση για χρηση σεαυτη
DE60239612D1 (de) Monodisperse mischungen und verfahren zur behandlung von diabetes
DE69521620D1 (de) Verwendung von 9-deoxyprostaglandinderivaten zur behandlung von glaukom
TR200401314T2 (tr) Sübstitüe edilmiş oksazolidinonlar ve bunların kullanımı
DE69918296D1 (de) N-substituierte aminotetraline als neuropeptid y y5 rezeptor-liganden und ihre anwendung zur behandlung von fettleibigkeit und anderen erkrankungen
ATE396174T1 (de) Hydroxyalkylaminderivate als beta-secretase- inhibitoren und deren verwendung zur behandlung der alzheimerschen krankheit oder ähnlicher krankheiten
DE69921156D1 (de) Verwendung von 5ht-6 antagonisten zur behandlung adhd
DE69830728D1 (de) Arzneimittel zur behandlung von häufigem wasserlassen und harninkontinenz
DE69527847T2 (de) Verwendung von anti-vegf-mitteln zur behandlung der endometriose
DE59609501D1 (de) Kristallmodifikation des CDCH, Verfahren zu dessen Herstellung und diese enthaltende pharmazeutische Zubereitungen
ATE236870T1 (de) Substituierte 2-phenyl-1-(3,4-dihydroxy-5- nitrophenyl)-1-ethanone, deren verwendung zur behandlung von erkrankungen des zentralen und periphären nervensystems und diese enthaltende pharmazeutische zusammensetzungen
ATE282413T1 (de) Verwendung von tempol zur behandlung von essentiellem hochdruck
ATE377657T1 (de) Serpin-arzneistoffe zur behandlung einer hiv- infektion und verfahren zu deren verwendung
ATE212834T1 (de) 2,2-dichloralkancarbonsäuren, verfahren zu ihrer herstellung diese enthaltende arzneimittel, und ihre verwendung zur behandlung der insulinresistenz
DE69804659D1 (de) 21-hydro-6,19-oxidoprogesterone (21oh-60p) und deren verwendung als arzneimittel zur behandlung von glukokortikoidüberschuss
DE69732709D1 (de) Expressionsblockierung von virulenten faktoren in s. aureus
DE69701346D1 (de) Verwendung von siliciumhaltigen Verbindungen zum Färben von Menschlichen Keratinfasern; neue Verbindungen und Zusammensetzungen, die diese enthalten.
ATE171372T1 (de) Verwendung eines antagonisten der substanz p zur behandlung von hautrötungen neurogen ursprungs
ATE173620T1 (de) Verwendung eines antagonisten von tnf-alpha zur behandlung von hautrötungen neurogenen ursprungs
DE69510356D1 (de) Anti-sickling beta-globin,zusammensetzung und verfahren zur behandlung von sichelzellanämie
ATE281841T1 (de) Verfahren zur herstellung von mikania extrakten enthaltend mikanolide und dihydromikanolide und verwendung in der behandlung proliferativer erkrankungen
ATE264309T1 (de) Substituierte caprolactam-derivate, diese enthaltende pharmazeutische zubereitungen sowie ihre verwendung zur behandlung von tumoren
DK1189627T3 (da) Sammensætninger indeholdende opløselige former af HLA-G til behandling af inflammatoriske patologiske tilstande i huden
ATE266027T1 (de) Optisch aktives pyridyl-4h-1,2,4-oxadiazinderivat und seine verwendung zur behandlung von gefässkrankheiten
DE50011660D1 (de) Gallensäure-substituierte phenyl-alkenoylguanidine, verfahren zu ihrer herstellung, ihre verwendung als medikamente oder diagnostika sowie sie enthaltende medikamente

Legal Events

Date Code Title Description
8364 No opposition during term of opposition